StreetInsider.com News Articles

Form 4 Alkermes plc. For: Oct 02 Filed by: Gaffin David Joseph

Fri, 02 Oct 2026 18:22:00 -0400

si-local-file:///var/storage/secattach/20261002/27143898.html

Form 144 Alkermes plc. Filed by: Gaffin David Joseph

Fri, 02 Oct 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20261002/27142051.html

Goldman Sachs Resumes Alkermes (ALKS) at Neutral

Thu, 24 Sep 2026 05:32:55 -0400

(Updated - September 24, 2026 5:32 AM EDT)

Goldman Sachs analyst Andrea Newkirk resumes coverage on Alkermes (NASDAQ: ALKS) with a Neutral rating and a price target of $50.00.

The analyst comments "ALKS is a global biopharmaceutical company with a mature portfolio of neuropsych assets (Aristada, Lybalvi, and Vivitrol for the treatment of schizophrenia, bipolar I disorder, alcohol dependence and opioid dependence, alongside Vumerity royalties and newly acquired Lumryz for narcolepsy). The clinical pipeline of orexin 2 receptor (OX2R) agonists include late-stage candidate alixorexton for narcolepsy and idiopathic hypersomnia (IH) and early-stage programs ALKS 7290 in attention-deficit hyperactivity disorder (ADHD) and ALKS

Goldman Sachs Resumes Alkermes (ALKS) at Neutral

Thu, 24 Sep 2026 05:32:55 -0400

(Updated - September 24, 2026 5:32 AM EDT)

Goldman Sachs analyst Andrea Newkirk resumes coverage on Alkermes (NASDAQ: ALKS) with a Neutral rating and a price target of $50.00.

Alkermes (ALKS) PT Raised to $61 at Baird

Tue, 22 Sep 2026 07:23:03 -0400

Baird analyst Joel Beatty raised the price target on Alkermes (NASDAQ: ALKS) to $61.00 (from $58.00) while maintaining a Outperform rating.

TD Cowen on Alkermes (ALKS): 'we view the update as important initial validation beyond sleep disorders'

Mon, 21 Sep 2026 10:04:28 -0400

TD Cowen analyst Joseph Thome reiterated a Buy rating and $58.00 price target on Alkermes (NASDAQ: ALKS).

The analyst comments "Alkermes reported topline Ph. Ib PoC results evaluating ALKS 7290, a selective OX2R agonist, in adults with ADHD. ALKS 7290 was generally well tolerated and provided the first clinical evidence that orexin agonism may improve ADHD symptoms. In the n=50 ADHD cohort, patients were randomized 4:1 within two cohorts to 20mg or 50mg total daily ALKS 7290, given in split doses, or placebo for 14 days after a two-week washout. As previously guided, the study was not powered for statistically significant

Stifel on Alkermes (ALKS): 'big picture we still think orexins have real potential in ADHD'

Mon, 21 Sep 2026 08:16:07 -0400

Stifel analyst Paul Matteis reiterated a Buy rating and $63.00 price target on Alkermes (NASDAQ: ALKS).

The analyst comments "We are reiterating our Buy rating on ALKS following positive signals in the ph1b from ALKS 7290, their orexin agonist for ADHD. In the 2wk study in ADHD patients, '7290 demonstrated AISRS reductions from baseline of 14/19points for the 20/50mg dose cohorts, and a 1-2point reduction in CGI-S, which, for 2 week efficacy, looks strong in the context of other studies (better than Strattera, nearing stimulants). The important caveat here though is that we do not know how this compares to placebo

Form 8-K Alkermes plc. For: Sep 21

Mon, 21 Sep 2026 07:11:00 -0400

si-local-file:///var/storage/secattach/20260921/27082908.html

Alkermes reports positive phase 1b results for ADHD drug ALKS 7290

Mon, 21 Sep 2026 07:00:38 -0400

Alkermes plc (Nasdaq: ALKS) announced positive topline results from a phase 1 proof-of-concept study of ALKS 7290, an investigational oral orexin 2 receptor agonist being developed for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults.

The phase 1b portion of the study enrolled 50 adults with ADHD in a double-blind, placebo-controlled trial. Participants received total daily doses of 20 mg or 50 mg of ALKS 7290 in split doses, or placebo, for 14 days following a two-week washout of existing ADHD medications. The study was not designed or powered to detect statistically significant differences between treatment groups.

On the Adult ADHD

Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

Mon, 21 Sep 2026 07:00:00 -0400

— ALKS 7290 is the First Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful Improvements in ADHD Symptoms in Adults —

— ALKS 7290 Was Generally Well Tolerated at All Doses Tested in Healthy Volunteers and Adults With ADHD —

— Phase 2 Study of ALKS 7290 in Adults With ADHD is Enrolling, Data Expected in 2027 —

DUBLIN--(BUSINESS WIRE)-- Alkermes plc (Nasdaq: ALKS) today announced positive topline results from a phase 1 proof-of-concept study evaluating ALKS 7290, the company’s novel, investigational orexin 2 receptor (OX2R) agonist in development for the treatment of

Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

Mon, 21 Sep 2026 07:00:00 -0400

— ALKS 7290 is the First Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful Improvements in ADHD Symptoms in Adults —

— ALKS 7290 Was Generally Well Tolerated at All Doses Tested in Healthy Volunteers and Adults With ADHD —

— Phase 2 Study of ALKS 7290 in Adults With ADHD is Enrolling, Data Expected in 2027 —

Form 3 Alkermes plc. For: Sep 14 Filed by: Whitaker Anne Clem

Fri, 18 Sep 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260918/27081093.html

Form 8-K Alkermes plc. For: Sep 14

Wed, 16 Sep 2026 09:12:00 -0400

si-local-file:///var/storage/secattach/20260916/27068362.html

Alkermes adds Anne Whitaker to its board of directors

Wed, 16 Sep 2026 07:00:34 -0400

Alkermes plc (NASDAQ: ALKS) has appointed Anne C. Whitaker as an independent member of its board of directors, the Dublin-based biopharmaceutical company announced.

Whitaker most recently served as chief executive officer of Aerami Therapeutics, a clinical-stage biopharmaceutical company. She previously held CEO roles at Novoclem Therapeutics and Synta Pharmaceuticals Corporation, and held senior positions at Bausch Health Companies, Sanofi and GlaxoSmithKline.

She currently serves on the boards of publicly traded companies Basilea Pharmaceutica and ICON plc, as well as several private companies including QurAlis, Bespak and Beaconcure Technologies. She holds a B.S. in chemistry from the University of North Alabama.

Blair Jackson, president

Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors

Wed, 16 Sep 2026 07:00:00 -0400

DUBLIN--(BUSINESS WIRE)-- Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Anne C. Whitaker, to the company’s Board of Directors (the Board). Ms. Whitaker is a seasoned biopharmaceutical executive and experienced board director who brings deep commercial and operational expertise, as well as a proven track record of driving growth and transformation across global pharmaceutical and biotechnology organizations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260915381220/en/

Anne C. Whitaker

“Anne joins

Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors

Wed, 16 Sep 2026 07:00:00 -0400

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260915381220/en/

Anne C. Whitaker

“Anne joins

Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program

Thu, 10 Sep 2026 07:00:00 -0400

— Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project —

— Areas of Interest Expanded to Include Narcolepsy and Idiopathic Hypersomnia in Addition to Schizophrenia and Bipolar I Disorder —

— Stage One Submission Period Runs From Sept. 11, 2026 Through Oct. 16, 2026 —

DUBLIN--(BUSINESS WIRE)-- Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards® program on Friday, Sept. 11, 2026. Now in its ninth year, this competitive grant program is designed to support the next generation of researchers working on

Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program

Thu, 10 Sep 2026 07:00:00 -0400

— Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project —

— Areas of Interest Expanded to Include Narcolepsy and Idiopathic Hypersomnia in Addition to Schizophrenia and Bipolar I Disorder —

— Stage One Submission Period Runs From Sept. 11, 2026 Through Oct. 16, 2026 —

Mizuho Reiterates Outperform Rating on Alkermes (ALKS)

Tue, 01 Sep 2026 03:55:56 -0400

Mizuho analyst Vamil Divan reiterated an Outperform rating and $65.00 price target on Alkermes (NASDAQ: ALKS).

The analyst comments "Given the level of inbound, we consulted with KOLs to gauge their expectations for ALKS-7290 Phase 1b readout in adult ADHD, expected this quarter. Given the inadequate powering (small sample, n=50), the KOLs don't expect ALKS-7290 to demonstrate statistical significance on efficacy measures (AISRS/relevant neuropsychological tests) but would like to see meaningful improvements over placebo. However, KOLs underscored that standard-of-care stimulants are highly effective and set a high efficacy bar, but they believe ALKS-7290 could potentially differentiate on overall safety/tolerability profile based

Alkermes narcolepsy drug data published in The Lancet Neurology